Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.

You may also be interested in...



Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review

FDA’s Oncologic Drugs Advisory Committee will consider the tyrosine kinase inhibitor for advanced renal cell carcinoma at a May 2 meeting. Aveo has attributed a negative overall survival trend in the TIVO-1 study to a crossover design and use of post-progression therapies among patients randomized to the comparator arm.

Preparing For Tivozanib Approval, Aveo Restructures With Staff Cuts

The Cambridge, Mass.-based company slows R&D and lays off 17% of its work force, but prepares to build a sales staff as it continues to reap auspicious data on the kidney cancer drug.

At Astellas R&D Day, Enzalutamide And In-house Tech In The Spotlight

Astellas has tried to build oncology knowhow in the past six years, and while licensed compounds approach approval, Phase II in-house compounds may show whether it can be a global leader.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel